BACKGROUND:N-acetylcysteine (NAC) has been shown not to alter the clinical outcome in chronic obstructive pulmonary disease (COPD) exacerbations. However, NAC may improve symptoms through its mucolytic effect in the subgroup of patients with increased sputum production. The aims of this study were to determine whether NAC improves symptoms and pulmonary function in patients with COPD exacerbation and increased sputum production. METHODS: This was a placebo-controlled study, where patients with severe COPD and increased sputum production, who were hospitalized for an exacerbation, were included. They were randomized to receive either NAC 200 mg tid or placebo in addition to the usual treatment. RESULTS:Forty-two patients were included and were equally distributed to NAC and placebo groups. The symptoms, namely, ease of sputum production and dyspnea at rest and on exertion significantly improved in both groups; but there was no difference in improvement between NAC and placebo groups (p = 0.96, 0.62, 0.31, respectively). Similarly, forced expiratory volume-one second (FEV1) andPaO2 levels improved significantly in NAC (964 ± 599-1239 ± 543 ml, p < 0.001, and 57.5 ± 14.5-70.5 ± 16.0 mmHg, p < 0.001, respectively) and placebo groups (981 ± 514-1180 ± 535 ml, p < 0.001 and 57.9 ± 14.3-68.7 ± 19.0 mmHg, p < 0.001, respectively), without any difference between the two groups (p = 0.52 and 0.57). There was no difference in the number of exacerbations during the 6-month follow-up period. CONCLUSION:NAC does not have any beneficial effect on clinical outcomes in patients with severe COPD exacerbation associated with increased and/or viscous mucus production.
RCT Entities:
BACKGROUND:N-acetylcysteine (NAC) has been shown not to alter the clinical outcome in chronic obstructive pulmonary disease (COPD) exacerbations. However, NAC may improve symptoms through its mucolytic effect in the subgroup of patients with increased sputum production. The aims of this study were to determine whether NAC improves symptoms and pulmonary function in patients with COPD exacerbation and increased sputum production. METHODS: This was a placebo-controlled study, where patients with severe COPD and increased sputum production, who were hospitalized for an exacerbation, were included. They were randomized to receive either NAC 200 mg tid or placebo in addition to the usual treatment. RESULTS: Forty-two patients were included and were equally distributed to NAC and placebo groups. The symptoms, namely, ease of sputum production and dyspnea at rest and on exertion significantly improved in both groups; but there was no difference in improvement between NAC and placebo groups (p = 0.96, 0.62, 0.31, respectively). Similarly, forced expiratory volume-one second (FEV1) and PaO2 levels improved significantly in NAC (964 ± 599-1239 ± 543 ml, p < 0.001, and 57.5 ± 14.5-70.5 ± 16.0 mmHg, p < 0.001, respectively) and placebo groups (981 ± 514-1180 ± 535 ml, p < 0.001 and 57.9 ± 14.3-68.7 ± 19.0 mmHg, p < 0.001, respectively), without any difference between the two groups (p = 0.52 and 0.57). There was no difference in the number of exacerbations during the 6-month follow-up period. CONCLUSION:NAC does not have any beneficial effect on clinical outcomes in patients with severe COPD exacerbation associated with increased and/or viscous mucus production.
Authors: Victor Kim; Jamie L Garfield; Carla L Grabianowski; Jason S Krahnke; John P Gaughan; Michael R Jacobs; Gerard J Criner Journal: COPD Date: 2011-04 Impact factor: 2.409
Authors: Marc Decramer; Maureen Rutten-van Mölken; P N Richard Dekhuijzen; Thierry Troosters; Cees van Herwaarden; Riccardo Pellegrino; C P Onno van Schayck; Dario Olivieri; Mario Del Donno; Wilfried De Backer; Ida Lankhorst; Alfredo Ardia Journal: Lancet Date: 2005 Apr 30-May 6 Impact factor: 79.321
Authors: S Blesa; J Cortijo; M Mata; A Serrano; D Closa; F Santangelo; J M Estrela; J Suchankova; E J Morcillo Journal: Eur Respir J Date: 2003-03 Impact factor: 16.671
Authors: Anthony J Fischer; Maria I Pino-Argumedo; Brieanna M Hilkin; Cullen R Shanrock; Nicholas D Gansemer; Anna L Chaly; Keyan Zarei; Patrick D Allen; Lynda S Ostedgaard; Eric A Hoffman; David A Stoltz; Michael J Welsh; Mahmoud H Abou Alaiwa Journal: JCI Insight Date: 2019-01-10
Authors: Martin Koppitz; Charlotte Eschenburg; Emilia Salzmann; Martin Rosewich; Ralf Schubert; Stefan Zielen Journal: PLoS One Date: 2016-06-16 Impact factor: 3.240
Authors: Stephen Milan; Praveen Bondalapati; Michael Megally; Eshan Patel; Pramil Vaghasia; Liam Gross; Elizabeth M Bachman; Puja Chadha; Jeremy A Weingarten Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-11-20